As of April 26, 2023, the percentage of adults 65 years and older who were fully vaccinated against COVID-19 had reached 94 percent. This statistic presents the percentage of adults 65 years and older in the United States with at least one dose or were fully vaccinated against COVID-19 as of April 26, 2023.

As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

According to a survey conducted monthly since December 2020, the share of respondents in the United States that said they would first wait until the vaccine has been available for a while to see how it is working for other people has decreased from 39 in December 2020 to four percent in the months January, February, and April 2022. On the other hand, the percentage of Americans who definetly would not receive a vaccination, in September dropped under 13 percent for the first time. However, it jumped up to 17 percent by April 2022. This statistic shows the percentage of adults in the United States who would get vaccinated against COVID-19 if a vaccine approved by the FDA was available for free.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 12+ and age 5+ denominators have been uploaded as archived tables.

Starting June 30, 2021, the dataset has been reconfigured so that all updates are appended to one dataset to make it easier for API and other interfaces. In addition, historical data has been extended back to January 5, 2021.

This dataset shows full, partial, and at least 1 dose coverage rates by zip code tabulation area (ZCTA) for the state of California. Data sources include the California Immunization Registry and the American Community Survey’s 2015-2019 5-Year data.

This is the data table for the LHJ Vaccine Equity Performance dashboard. However, this data table also includes ZTCAs that do not have a VEM score.

This dataset also includes Vaccine Equity Metric score quartiles (when applicable), which combine the Public Health Alliance of Southern California’s Healthy Places Index (HPI) measure with CDPH-derived scores to estimate factors that impact health, like income, education, and access to health care. ZTCAs range from less healthy community conditions in Quartile 1 to more healthy community conditions in Quartile 4.

The Vaccine Equity Metric is for weekly vaccination allocation and reporting purposes only. CDPH-derived quartiles should not be considered as indicative of the HPI score for these zip codes. CDPH-derived quartiles were assigned to zip codes excluded from the HPI score produced by the Public Health Alliance of Southern California due to concerns with statistical reliability and validity in populations smaller than 1,500 or where more than 50% of the population resides in a group setting.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

For some ZTCAs, vaccination coverage may exceed 100%. This may be a result of many people from outside the county coming to that ZTCA to get their vaccine and providers reporting the county of administration as the county of residence, and/or the DOF estimates of the population in that ZTCA are too low. Please note that population numbers provided by DOF are projections and so may not be accurate, especially given unprecedented shifts in population as a result of the pandemic.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

As of January 2021, around 22 percent of U.S. adults stated they would not get a vaccine that protects against the coronavirus if one becomes available. This statistic depicts the proportion of U.S. adults who would get a coronavirus vaccine if it became available from January 2020 to January 2021.

As of April 26, 2023, one of the states with the highest percentage of adults 65 years and older who were fully vaccinated against COVID-19 was Vermont with 95 percent. This statistic shows the percentage of adults aged 65 and older in the United States who were fully vaccinated against COVID-19 as of April 26, 2023, by state or territory.

Between December 2020 and April 2021, COVID-19 vaccination coverage was nearly 7 percent higher in urban areas compared to rural areas. This statistic shows the percentage of adults in urban vs rural U.S. vaccinated against COVID-19 from December 2020 to April 2021.

The global human vaccine market is poised for significant expansion, projected to reach approximately USD 32,870 million by 2025. This growth is driven by a robust Compound Annual Growth Rate (CAGR) of 4.4%, indicating sustained and healthy market development over the forecast period of 2025-2033. A confluence of factors is fueling this upward trajectory, including increasing healthcare expenditure globally, a heightened awareness regarding the preventive power of vaccinations, and ongoing advancements in vaccine technology. The rising incidence of infectious diseases, coupled with expanding vaccination programs for both pediatric and adult populations, further bolsters market demand. Furthermore, the development of novel vaccines for emerging diseases and the continuous efforts in research and development by major pharmaceutical and biotechnology companies are key contributors to this positive market outlook. The market is segmented by vaccine type, encompassing a wide array of essential immunizations such as Varicella, Influenza, Polio, Hepatitis A, Rabies, BCG, Hepatitis B, Pertussis, Diphtheria, Tetanus, Pneumococcal, and Rotavirus vaccines. Each segment is experiencing varying degrees of growth influenced by disease prevalence, public health initiatives, and the introduction of new and improved vaccine formulations. The application landscape is equally diverse, covering both adult and pediatric demographics. Geographically, the Asia Pacific region is emerging as a significant growth engine, owing to its large population base, increasing disposable income, and expanding healthcare infrastructure, alongside substantial investments in vaccine manufacturing and distribution. North America and Europe continue to be mature yet vital markets, characterized by high vaccination rates and a strong emphasis on preventative healthcare.

The global Adult Vaccines Market size is expected to expand from USD 22.48 billion in 2024 to USD 41.02 billion by 2034, demonstrating a CAGR of more than 6.2% between 2025 and 2034. Key industry players include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, AstraZeneca, Novartis, CSL Limited, Emergent BioSolutions, Johnson & Johnson, Serum Institute of India.

The global Component DTP Vaccine market is poised for significant growth, projected to reach an estimated market size of approximately USD 8,500 million by 2025. This expansion is driven by a confluence of factors, including increasing awareness of vaccine-preventable diseases, robust government immunization programs, and the continuous development of more effective and safer vaccine formulations. The market is expected to witness a Compound Annual Growth Rate (CAGR) of around 6.5% over the forecast period of 2025-2033. Key growth drivers include the rising incidence of pertussis, diphtheria, and tetanus globally, prompting greater demand for DTP vaccines, particularly in developing economies. Furthermore, advancements in vaccine technology, leading to the introduction of combination vaccines that offer broader protection, are fueling market expansion. The pediatric segment continues to be the dominant application, owing to routine immunization schedules, while the adult segment is showing increasing traction due to booster shots and specific risk group vaccinations. The market is segmented into two-component, three-component, and five-component vaccines, with the three-component DTaP (diphtheria, tetanus, and acellular pertussis) vaccine holding a substantial market share due to its widespread adoption and proven efficacy. The competitive landscape of the Component DTP Vaccine market is characterized by the presence of several major global players, including Sanofi, GSK, CNBG, Hualan Biological Vaccine, BioKangtai, Walvax Biotechnology, and CanSino Biologics. These companies are actively engaged in research and development to enhance vaccine efficacy, expand product portfolios, and secure regulatory approvals in key markets. Strategic collaborations, mergers, and acquisitions are also prevalent as companies aim to consolidate their market positions and tap into emerging opportunities. The Asia Pacific region is anticipated to emerge as a significant growth hub, driven by a large and growing population, increasing healthcare expenditure, and government initiatives to bolster vaccination coverage. North America and Europe remain mature markets with high vaccination rates, contributing consistently to market demand. However, challenges such as vaccine hesitancy, the high cost of some advanced formulations, and the need for robust cold chain infrastructure in certain regions may temper the market's growth trajectory. Despite these restraints, the fundamental need for DTP vaccination for public health ensures a sustained and growing demand for these critical vaccines. This report provides an in-depth analysis of the global Component DTP Vaccine market, offering a comprehensive overview from 2019 to 2033. With 2025 serving as both the base and estimated year, the forecast period of 2025-2033 will reveal significant market dynamics. The historical period of 2019-2024 sets the foundation for understanding past performance. We project the market to reach a significant volume, potentially exceeding 1500 million units by 2025, with substantial growth anticipated throughout the forecast period.

Between December 2020 and April 2021, for both women and men, COVID-19 vaccination coverage decreased moving down the urban-rural continuum. However, women generally had a higher vaccination rate. This gap was widest in adults living in large fringe metropolitan areas where 48.8 percent of women compared to 41.8 percent of men were vaccinated. This statistic shows the percentage of adults in the U.S. vaccinated against COVID-19 from December 2020 to April 2021, by their gender and their county's six-level urban-rural classification.

Diphtheria Tetanus Pertussis Vaccine Market Outlook

The global market size for Diphtheria Tetanus Pertussis (DTP) vaccine was valued at approximately USD 3.5 billion in 2023 and is projected to reach around USD 5.8 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period. The growth of this market is largely driven by increasing government initiatives for immunization, rising awareness about vaccine-preventable diseases, and advancements in vaccine technology.

One of the primary growth factors in the DTP vaccine market is the strong support from government programs and international organizations such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF). These organizations are actively involved in promoting vaccination to prevent the spread of these potentially deadly diseases. Large-scale immunization programs, especially in developing countries, are significantly boosting the demand for DTP vaccines. Furthermore, mandatory vaccination policies in many regions and the inclusion of DTP vaccines in national immunization schedules are providing a consistent market demand.

Advancements in biotechnology and vaccine formulation are also major contributors to market growth. Modern DTP vaccines are safer and more effective, with fewer side effects compared to earlier versions. The introduction of combination vaccines, which include DTP along with other immunizations such as H. influenzae type B (Hib) and Hepatitis B, has made immunization programs more efficient and improved compliance rates. Additionally, continuous research and development efforts are leading to the development of new vaccine formulations that can offer broader protection and longer-lasting immunity.

Rising awareness among parents and caregivers about the importance of vaccination is another significant growth driver. Educational campaigns and outreach programs are helping to dispel myths and misinformation about vaccines, leading to higher vaccination rates. This is particularly important in combating vaccine hesitancy, which remains a challenge in many parts of the world. Increased awareness is also leading to higher demand for booster doses, ensuring continued immunity through adolescence and adulthood.

From a regional perspective, the market dynamics vary significantly across different geographies. For instance, North America and Europe have well-established immunization programs and high coverage rates, primarily driven by strong healthcare infrastructure and supportive government policies. On the other hand, regions like Asia Pacific and Latin America are witnessing rapid growth due to increasing healthcare access, growing population, and rising public health initiatives. Africa and the Middle East present significant opportunities for market expansion, albeit with challenges related to healthcare infrastructure and access.

Vaccine Type Analysis

The Diphtheria Tetanus Pertussis vaccine market by vaccine type can be segmented into DTaP, Tdap, and Td. The DTaP segment holds a significant share due to its widespread use in pediatric vaccination programs. DTaP vaccines, which combine antigens for diphtheria, tetanus, and acellular pertussis, are the standard for initial immunizations in infants and young children. The safety profile and efficacy of DTaP vaccines make them the preferred choice for pediatricians and parents alike, contributing to their dominance in the market.

The Tdap segment is experiencing substantial growth, driven by recommendations for booster doses in adolescents and adults. Unlike DTaP, which is primarily for young children, Tdap is formulated to provide continued protection against these diseases as immunity from initial vaccinations wanes. Healthcare professionals strongly advocate for Tdap boosters during adolescence, pregnancy, and in adults who have not previously received the vaccine, further fueling the demand. The increasing awareness of pertussis outbreaks and the need for booster vaccinations are key factors in the rising adoption of Tdap vaccines.

The Td vaccine segment, while smaller than DTaP and Tdap, remains crucial, particularly in adult immunization schedules. Td vaccines offer protection against tetanus and diphtheria and are recommended for adults who need tetanus boosters but do not require pertussis immunization. Public health guidelines and occupational hea

The global vaccines market, segmented into adult and pediatric vaccines, presents a significant growth opportunity. Driven by increasing vaccination rates, rising prevalence of vaccine-preventable diseases, and continuous advancements in vaccine technology, the market is projected to experience substantial expansion over the forecast period (2025-2033). While precise market size figures for 2019-2024 are unavailable, leveraging the provided 5% CAGR and a 2025 market size estimate of $XX billion (a realistic estimate considering global vaccine market sizes reported by credible sources), we can project a considerable growth trajectory. Assuming a consistent CAGR of 5%, the market is poised to reach approximately $YY billion by 2033. This growth is further fueled by the introduction of novel vaccines, including mRNA vaccines, and increasing government initiatives to promote vaccination programs globally. The adult vaccine segment, characterized by a higher average price point per dose compared to pediatric vaccines, will likely contribute significantly to the overall market value. However, the pediatric vaccine segment is expected to witness robust growth driven by the expanding child population, especially in developing economies. The market is geographically diversified, with North America and Europe currently holding significant market shares, driven by high healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific and other regions are anticipated to experience faster growth rates, due to increasing healthcare awareness and investments in immunization programs. The distribution channels for vaccines primarily include hospitals and medical care centers, indicating a strong reliance on healthcare infrastructure. However, the "Others" segment, which may include pharmacies and specialized clinics, is also expected to grow as accessibility and convenience in vaccine administration increase. Competition is intense among key players like GlaxoSmithKline, Sanofi, Merck, Novartis, Pfizer, AstraZeneca, Johnson & Johnson, Takeda Pharmaceutical, Bavarian Nordic, LG Life Sciences, Sinovac Biotech, and others. These companies are actively involved in research and development, strategic partnerships, and geographic expansion to solidify their market presence and capitalize on the growth opportunities within the adult and pediatric vaccine markets. Market restraints, however, could include vaccine hesitancy, logistical challenges in vaccine distribution, particularly in remote areas, and regulatory hurdles in certain markets.

The global Hepatitis A and B combined vaccine market is experiencing robust growth, driven by increasing awareness of the diseases, rising vaccination rates, particularly in developing nations, and the expanding elderly population, which is more susceptible to these infections. Government initiatives promoting vaccination programs and the continuous development of more effective and safer vaccines are further fueling market expansion. While challenges exist, including vaccine hesitancy in certain regions and the high cost of vaccination programs in low-income countries, the overall market trajectory is positive. Let's assume a 2025 market size of $2.5 billion (this is an estimation based on typical sizes of vaccine markets and would need to be replaced with the actual value if available), and a Compound Annual Growth Rate (CAGR) of 7% for the forecast period of 2025-2033. This implies substantial growth, reaching an estimated market value of approximately $4.5 billion by 2033. The market is segmented by vaccine type (live virus vs. inactivated virus) and application (pediatric vs. adult), reflecting the diverse needs and risk profiles of different populations. Key players like GSK and Sinovac are actively competing in this space through product innovation and market penetration strategies. Regional variations exist; North America and Europe currently hold larger market shares due to higher vaccination rates and advanced healthcare infrastructure, yet the Asia-Pacific region is projected to exhibit the fastest growth rate owing to increasing healthcare spending and rising vaccination coverage in developing economies. The market's future hinges on the effectiveness of ongoing public health initiatives, the affordability and accessibility of vaccines, especially in underserved areas, and further innovations in vaccine technology, leading to improved efficacy, safety, and reduced administration costs. The development of combination vaccines that offer broader protection against hepatitis viruses and other infectious diseases could also stimulate future market growth. Addressing vaccine hesitancy through educational campaigns and bolstering supply chain resilience in developing nations remain crucial to ensuring universal access and maximizing the impact of vaccination programs in curbing Hepatitis A and B infections globally.

The global Tetanus Vaccine (Adsorbed) market is poised for significant expansion, projected to reach an estimated $1.5 billion in 2025, with a robust Compound Annual Growth Rate (CAGR) of approximately 8.5% anticipated throughout the forecast period of 2025-2033. This growth is primarily propelled by increasing global awareness surrounding the preventable nature of tetanus infections and the critical role of vaccination in public health initiatives. Rising demand for combination vaccines, which offer protection against multiple diseases with a single injection, is a key driver, simplifying immunization schedules for both healthcare providers and recipients. Furthermore, the growing emphasis on routine childhood immunization programs, coupled with proactive adult booster shot campaigns, underscores the sustained demand for tetanus vaccines. Government mandates for vaccination in schools and workplaces, alongside expanded access to healthcare services in emerging economies, are also contributing to market buoyancy. The evolving landscape of infectious disease prevention and control is expected to further solidify the market's upward trajectory. The market is segmented by vaccine type, with Combined Vaccines holding a substantial share due to their convenience and efficacy in providing broad-spectrum protection. Applications span across children, teenagers, and adults, reflecting the lifelong need for tetanus immunization. Geographically, the Asia Pacific region is emerging as a significant growth engine, driven by large populations, increasing healthcare expenditure, and government-led vaccination drives, particularly in countries like India and China. North America and Europe remain mature yet stable markets, characterized by high vaccination rates and a strong presence of leading vaccine manufacturers such as Sanofi Pasteur and GSK. Restraints such as potential vaccine hesitancy in certain demographics and the high cost of research and development for new vaccine formulations are present but are largely offset by the overwhelming public health benefits and ongoing efforts to ensure vaccine affordability and accessibility. Here is a unique report description for Tetanus Vaccine (Adsorbed), incorporating the requested elements:

The global Measles, Mumps, and Rubella (MMR) Virus Vaccine Live market is projected to reach a significant valuation of approximately $5,500 million by 2025, with an anticipated Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period of 2025-2033. This robust growth is primarily propelled by heightened public health awareness campaigns, increasing government initiatives focused on disease eradication, and the persistent threat of infectious disease outbreaks. The rising incidence of measles, mumps, and rubella, particularly in developing regions, further fuels demand for effective vaccination strategies. Advancements in vaccine technology and the development of more stable and accessible formulations are also contributing to market expansion. The market is characterized by a strong emphasis on routine immunization programs, making both hospital and community settings crucial distribution channels. The pediatric segment dominates market share due to the critical importance of early vaccination for children, while adult vaccination, driven by catch-up programs and immune status checks, represents a growing segment. The market dynamics are influenced by several key drivers, including the global push for achieving herd immunity against these preventable diseases and the continuous efforts by organizations like the WHO to strengthen vaccination coverage. However, certain restraints, such as vaccine hesitancy, logistical challenges in remote areas, and stringent regulatory processes for new vaccine introductions, could temper the market's full potential. Major players like Merck, Shanghai Institute of Biological Products, and Beijing Tiantan Biological Products are actively engaged in research and development, seeking to enhance vaccine efficacy and accessibility. Geographically, North America and Europe currently hold substantial market shares due to well-established healthcare infrastructures and high vaccination rates. The Asia Pacific region, however, is poised for significant growth, driven by large populations, increasing healthcare expenditure, and government-led immunization drives. Here is a unique report description for Measles, Mumps and Rubella Virus Vaccine Live, incorporating your provided information and structure:

Baseline characteristics of all patients in N3C receiving 2 doses of mRNA vaccine between January 1, 2021, and September 21, 2021.

The Viral Vaccines Market is Segmented by Form (Liquid Vaccines and Lyophilized Vaccines), Type (Live-Attenuated, Inactivated, and More), Approach (Therapeutic and Preventive), Age Group (Pediatric, Adult, and Geriatric), Distribution Channel (Public and Private) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market and Forecasts are Provided in Terms of Value (USD).

Discover the booming global Mono Hepatitis B Vaccine market, projected to reach $1208.5 million in 2025 with a robust CAGR. This in-depth analysis covers market size, drivers, trends, restraints, key players (GSK, Merck, Serum Institute), and regional breakdowns. Learn about yeast-derived and CHO-derived vaccines, and the future of Hepatitis B prevention.